Compound overview
Retatrutide: a triple-agonist research overview
Retatrutide is a synthetic triple-agonist peptide that acts at three receptors simultaneously — GLP-1, GIP and glucagon. This triple-receptor profile makes it the most recent focus of comparative incretin research.
Triple-receptor mechanism
Retatrutide activates the GLP-1, GIP and glucagon receptors together, the broadest receptor profile in the incretin-agonist class studied to date.
Comparative incretin research
It is studied alongside the dual-agonist tirzepatide and the GLP-1 agonist semaglutide.
Research quantities
It is referenced across metabolic and endocrine research models, and is supplied in both 10 mg and 20 mg research quantities.
This overview is provided for educational and laboratory-research purposes only. It summarises published research and proposed mechanisms; it is not medical advice and does not describe or recommend human or veterinary use. Products are supplied strictly for laboratory research use only — not for human or veterinary consumption, and not a drug, food or cosmetic.